Researchers at the University of Arizona have discovered that metformin, a drug commonly used to treat type 2 diabetes, might also be used to treat heart failure with preserved ejection fraction (HFpEF), a condition that is predicted to affect over 8% of people ages 65 or older by the year 2020. The study, which was published in the Journal of General Physiology, shows that metformin relaxes a key heart muscle protein called titin, allowing the heart to properly fill with blood before pumping it around the body.
A cross-sectional study conducted at MedUni Vienna including patients with chronic systolic heart failure has demonstrated great variations in patients' individual therapy response to ACE inhibitors, the first-line therapy for heart failure. It seems possible that the clinical picture is composed of various subgroups characterized by the over-activation of different endogenous systems. The results provide an explanatory approach to the question, why not all patients benefit equally from ACE inhibitors. The study supports ongoing efforts to develop a targeted, individualised therapy for heart failure patients (precision medicine).
For people living with both Type 2 diabetes and heart failure, taking an aspirin each day appears to lower the risk of dying or being hospitalized for heart failure, according to research being presented at the American College of Cardiology’s 67th Annual Scientific Session. But the data also reveal aspirin use may increase the risk of nonfatal heart attack or stroke, a somewhat contradictory finding that surprised researchers.
Middle-aged couch potatoes may reduce or reverse the risk of heart failure associated with years of sitting if they participate in two years of regular aerobic exercise training, according to a new study in the American Heart Association’s journal Circulation.
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of Warwick, the Baker Institute and Monash University.
There is strong evidence of that aerobic exercise, strength training and condition-specific therapeutic exercise affect positively on the functional capacity of patients with chronic diseases. This is revealed in an extensive systematic analysis of published research data by the Faculty of Sport and Health Sciences, University of Jyväskylä, Finland. The systematic review of meta-analyses evaluates the effects of exercise therapy on more than twenty of the most common chronic diseases such as osteoarthritis, rheumatoid arthritis, coronary artery disease, heart failure, type 2 diabetes, different types of cancers, and Alzheimer’s disease.